🏥
🏥 Health
Biotechs pour billions into curing rare liver disease AATD in high-stakes race
Alpha-1 antitrypsin deficiency (AATD), a rare liver disease caused by a single DNA mutation, has become the focus of a multi-billion-dollar biotech race. The condition causes the liver to produce a mutant protein that fails to protect the lungs, leading to progressive damage. The competition involves duelling technologies, patent wars, a broken alliance and intensifying rivalry between US and Chinese pharmaceutical industries.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!